Lynn Yap

Lynn Yap

Auto-generated profile, based on publicly available information

Lynn Yap

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RNRhea Nadkarni
Rhea Nadkarni
WCWern Cui Chu
Wern Cui Chu
CLCheryl Q.E. Lee
Cheryl Q.E. Lee
Yasir MohamudYasir Mohamud
Yasir Mohamud
LYLynn Yap
Lynn Yap
LHLena Ho
Lena Ho
Nucleotide-binding oligomerization domain (NBD), leucine-rich repeat (LRR) containing protein family (NLRs) are intracellular pattern recognition receptors that mediate innate immunity against infections. The endothelium is the first line of defense against blood-borne pathogens, but it is unclear which NLRs control endothelial cell (EC) intrinsic immunity. Here, we demonstrate that human ECs simultaneously activate NLRP1 and CARD8 inflammasomes in response to DPP8/9 inhibitor Val-boro-Pro (VbP). Enterovirus Coxsackie virus B3 (CVB3)—the most common cause of viral myocarditis—predominantly activates CARD8 in ECs in a manner that requires viral 2A and 3C protease cleavage at CARD8 p.G38 and proteasome function. Genetic deletion of CARD8 in ECs and human embryonic stem cell–derived cardiomyocytes (HCMs) attenuates CVB3-induced pyroptosis, inflammation, and viral propagation. Furthermore, using a stratified endothelial–cardiomyocyte co-culture system, we demonstrate that deleting CARD8 in ECs reduces CVB3 infection of the underlying cardiomyocytes. Our study uncovers the unique role of CARD8 inflammasome in endothelium-intrinsic anti-viral immunity.

26 May 2023 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
LYLynn Yap
Lynn Yap
LCLi Yen Chong
Li Yen Chong
CTClarissa Tan
Clarissa Tan
SASwarnaseetha Adusumalli
Swarnaseetha Adusumalli
MSMillie Seow
Millie Seow
KTKarl Tryggvason
Karl Tryggvason
Ischemic heart disease, which is often associated with irreversibly damaged heart muscle, is a major global health burden. Here, we report the potential of stem cell-derived committed cardiac progenitors (CCPs) have in regenerative cardiology. Human pluripotent embryonic stem cells were differentiated to CCPs on a laminin 521 + 221 matrix, characterized with bulk and single-cell RNA sequencing, and transplanted into infarcted pig hearts. CCPs differentiated for eleven days expressed a set of genes showing higher expression than cells differentiated for seven days. Functional heart studies revealed significant improvement in left ventricular ejection fraction at four and twelve weeks following transplantation. We also observed significant improvements in ventricular wall thickness and a reduction in infarction size after CCP transplantation (p-value < 0.05). Immunohistology analyses revealed in vivo maturation of the CCPs into cardiomyocytes (CM). We observed temporary episodes of ventricular tachyarrhythmia (VT) in four pigs and persistent VT in one pig, but the remaining five pigs exhibited normal sinus rhythm. Importantly, all pigs survived without the formation of any tumors or VT-related abnormalities. We conclude that pluripotent stem cell-derived CCPs constitute a promising possibility for myocardial infarction treatment and that they may positively impact regenerative cardiology.

24 February 2021 in ACS Synthetic Biology
Verified
Journal Article
Open access
XCXin Yi Choo
Xin Yi Choo
YLYu Ming Lim
Yu Ming Lim
KKKhairunnisa Katwadi
Khairunnisa Katwadi
LYLynn Yap
Lynn Yap
KTKarl Tryggvason
Karl Tryggvason
OROwen J. L. Rackham
Owen J. L. Rackham
The combination of single-cell RNA sequencing with CRISPR inhibition/activation provides a high-throughput approach to simultaneously study the effects of hundreds if not thousands of gene perturbations in a single experiment. One recent development in CRISPR-based single-cell techniques introduces a feature barcoding technology that allows for the simultaneous capture of mRNA and guide RNA (gRNA) from the same cell. This is achieved by introducing a capture sequence, whose complement can be incorporated into each gRNA and that can be used to amplify these features prior to sequencing. However, because the technology is in its infancy, there is little information available on how such experimental parameters can be optimized. To overcome this, we varied the capture sequence, capture sequence position, and gRNA backbone to identify an optimal gRNA scaffold for CRISPR activation gene perturbation studies. We provide a report on our screening approach along with our observations and recommendations for future use.

11 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SASwarnaseetha Adusumalli
Swarnaseetha Adusumalli
SLSamantha Lim
Samantha Lim
VRVincent Ren
Vincent Ren
LCLi Yen Chong
Li Yen Chong
CTClarissa Tan
Clarissa Tan
LYLynn Yap
Lynn Yap
Ischemic heart disease is the most prevalent cause of death globally. Regenerative cardiology using stem cell-based therapy is a potential approach to replace infarcted myocardial (MI) heart tissue. We used cardiovascular progenitors (CVPs) derived from human pluripotent embryonic stem cells differentiated to cardiomyocyte progenitors on a laminin 521+221 matrix and transplanted them into acute and chronic MI pig hearts (AMI and CMI). We performed time-series spatial transcriptomics to characterize these human cells at AMI 1- and 2- and at CMI 1-, 4- and 12 weeks post-transplantation. Both models showed high transcriptional reproducibility in the replicates. Furthermore, the human grafts engrafted well, matured, and expressed metabolic, ribosomal, T-tubule, and channel-related genes in the human graft over time. Cell-cell communication analysis revealed Midkine (MDK) signaling as a key pathway that may lead to increased angiogenesis of collaterals in the human graft.

31 July 2026 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
SASwarnaseetha Adusumalli
Swarnaseetha Adusumalli
KLKye Siong Leong
Kye Siong Leong
SLSamantha Lim
Samantha Lim
VRVincent Ren
Vincent Ren
LCLi Yen Chong
Li Yen Chong
LYLynn Yap
Lynn Yap

29 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LYLynn Yap
Lynn Yap
LCLi Yen Chong
Li Yen Chong
CTClarissa Tan
Clarissa Tan
SASwarnaseetha Adusumalli
Swarnaseetha Adusumalli
MSMillie Seow
Millie Seow
KTKarl Tryggvason
Karl Tryggvason
Background: Ischemic heart disease is a huge global burden where patients often have irreversibly damaged heart muscle. State-of-the-art technology using stem cell-derived products for cellular therapy could potentially replace damaged heart muscle for regenerative cardiology. Methods and Results: Pluripotent human embryonic stem cells (hESCs) were differentiated on a laminin LN521+221 matrix to cardiovascular progenitors (CVPs). Global transcriptome analyses at multiple time points by single-cell RNA-sequencing demonstrated high reproducibility (R 2 > 0.95) between two hESCs lines. We identified several CVP signature genes as quality batch control parameters which are highly specific to our CVPs as compared to canonical cardiac progenitor genes. A total of 200 million CVPs were injected into the infarcted region caused by permanent ligation of the coronary arteries of 10 immunosuppressed pigs and maintained for 4- and 12-weeks post transplantation. The transplanted cells engrafted and proliferated in the infarcted area as indicated by IVIS imaging, histology staining and spatial transcriptomic analysis. Spatial transcriptomic analysis at 1 week following transplantation showed that the infarcted region expressed human genes in the same area as immunohistology sections. Heart function was analyzed by magnetic resonance imaging (MRI) and computerized tomography (CT). Functional studies revealed overall improvement in left ventricular ejection fraction by 21.35 ± 3.3 %, which was accompanied by significant improvements in ventricular wall thickness and wall motion, as well as a reduction in infarction size after CVP transplantation as compared to medium control pigs (P < 0.05). Immunohistology analysis revealed maturation of the CVPs to cardiomyocytes (CMs) where the human grafts aligned with host tissue forming end-to-end connections typical for heart muscle. Electrophysiology analyses revealed electric continuity between injected and host tissue CMs. Episodes of ventricular tachyarrhythmia (VT) over a period of 25 days developed in four pigs, one pig had persistent VT, while the rest remained in normal sinus rhythm. All ten pigs survived the experiment without any VT-related death. Conclusions: We report a highly reproducible, chemically defined and fully humanized differentiation method of hESCs for the generation of potent CVPs. This method may pave the way for lasting stem cell therapy of myocardial infarction (MI) in humans. Clinical Perspective: What is New?: We present a highly reproducible, chemically defined and fully humanized laminin-based differentiation method for generation of large amounts of cardiovascular progenitors (CVP); 20 million cells in a 10 cm 2 culture dish which were used for a preclinical study in pigs. Transplantation of the CVPs into the myocardial infarcted pig hearts yields maturation of the progenitor cells to cardiomyocytes (CMs) and improved cardiac function (21.35 ± 3.3 % LVEF improvement) using only 200 million CVPs. Temporary episodes of ventricular arrhythmia (50%) were observed after CVP transplantation. No fatal ventricular arrhythmia occurred. What are the clinical implications?: Our laminin-based approach generated potent CVPs in vivo and largely restored function of the damaged heart. Cardiovascular progenitors may provide a new and safe therapeutic strategy for myocardial infarction. The results may have a significant impact on regenerative cardiology.